A detailed history of E Fund Management Co., Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 18,710 shares of ABBV stock, worth $3.68 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
18,710
Previous 13,177 41.99%
Holding current value
$3.68 Million
Previous $2.4 Million 33.76%
% of portfolio
0.18%
Previous 0.15%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $856,453 - $1 Million
5,533 Added 41.99%
18,710 $3.21 Million
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $992,162 - $1.13 Million
6,208 Added 89.08%
13,177 $2.4 Million
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $75,680 - $85,233
550 Added 8.57%
6,969 $1.08 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $58,913 - $68,200
-441 Reduced 6.43%
6,419 $957,000
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $45,185 - $56,230
341 Added 5.23%
6,860 $924,000
Q1 2023

May 11, 2023

SELL
$144.61 - $166.54 $22,414 - $25,813
-155 Reduced 2.32%
6,519 $1.04 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $165,418 - $198,380
-1,196 Reduced 15.2%
6,674 $1.08 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $82,136 - $94,205
612 Added 8.43%
7,870 $1.06 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $177,116 - $225,173
1,287 Added 21.55%
7,258 $1.11 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $38,538 - $47,815
-292 Reduced 4.66%
5,971 $968,000
Q4 2021

Feb 11, 2022

SELL
$107.43 - $135.93 $47,484 - $60,081
-442 Reduced 6.59%
6,263 $848,000
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $151,407 - $171,869
1,423 Added 26.94%
6,705 $723,000
Q1 2021

May 12, 2021

BUY
$102.3 - $112.62 $540,348 - $594,858
5,282 New
5,282 $571,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $348B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.